Certain Drugs Distributed by the National Cancer Institute — NCD 141 | CMS Coverage Update

TL;DR: The Centers for Medicare & Medicaid Services modified NCD 141 governing Group C drug coverage under the National Cancer Institute's distribution program, with an effective date of March 7, 2026. Here's what billing teams need to know.

CMS Group C drug coverage policy has been a quiet corner of oncology billing for years — but a modification to NCD 141 in the CMS system means your billing team should revisit how you document and bill for these drugs. This policy does not list specific CPT or HCPCS codes, but it directly affects reimbursement for NCI-distributed oncology drugs billed under Drugs and Biologicals, Inpatient Hospital Services, and Oral Anticancer Drug benefit categories.

Quick-Reference Table

CMS Group C Drug Coverage Criteria and Medical Necessity Requirements 2026

NCD 141 is the National Coverage Determination governing Medicare coverage of drugs distributed by the National Cancer Institute's Division of Cancer Treatment. Specifically, it covers a category called Group C drugs — oncology agents that the NCI and FDA have cleared for use outside of clinical trials.

That last point matters. Most investigational drugs distributed by NCI require enrollment in a clinical trial. Group C drugs are different. The NCI designates a drug as Group C only when there's sufficient evidence of efficacy in a specific tumor type and the drug can be safely administered outside a trial setting. That's a meaningful distinction for your billing team.

Under this CMS coverage policy, Medicare Administrative Contractors may presume a Group C drug and its related hospital stay are covered — assuming all other applicable coverage requirements are met. But that presumption depends on four hard requirements at the physician level.

The Four Physician-Level Requirements

For a physician to receive and use Group C drugs from the NCI, all four of the following must be satisfied:

From a medical necessity standpoint, CMS is essentially outsourcing the clinical gatekeeping to the NCI. If the NCI controls distribution and the physician has met all four requirements, the MAC can assume coverage without a separate medical necessity determination. That's actually useful — it removes one layer of review.

The real issue here is documentation. Your claim's coverage rests entirely on whether those four requirements are satisfied and provable at audit. If a MAC has reason to question coverage, it can escalate to a Quality Improvement Organization for review. That's your signal to keep physician registration and adverse event reporting records tight.

Prior authorization is not explicitly required under this policy, but the four-step physician registration and request process functions as a de facto prior authorization mechanism through the NCI. Don't treat the absence of a formal prior auth requirement as meaning there's no documentation burden. There is.

CMS Group C Drug Exclusions and Non-Covered Indications

The NCD 141 coverage policy has a clear boundary: coverage applies only to indications outlined in the NCI's guidelines for the specific drug. Use outside those guidelines is not covered.

This isn't gray area. If a physician administers a Group C drug for a tumor type not listed in the NCI's approved indications, the presumption of coverage disappears. The MAC is no longer required to assume the claim is valid. You're looking at a potential claim denial with no policy support to appeal from.

The other exclusion is implicit: physicians who have not completed FD-Form 1573 and registered with the NCI as investigators are simply ineligible to receive Group C drugs through this program. Any claim tied to an unregistered physician is exposed.

Coverage Indications at a Glance

CMS Group C Drug Billing Guidelines and Action Items 2026

The modification effective March 7, 2026 is your prompt to audit your current Group C drug billing practices. Here's what to do.

If your group has a high volume of oncology drug claims and you're not confident about your documentation across all seven points above, loop in your compliance officer before March 7, 2026. The presumption of coverage the MAC extends under NCD 141 is a real advantage — but it evaporates the moment documentation gaps surface at audit.

CPT, HCPCS, and ICD-10 Codes for NCI Group C Drugs Under NCD 141

Coverage Status for Codes Under NCD 141

NCD 141 does not list specific CPT, HCPCS, or ICD-10 codes. This is not unusual for older National Coverage Determinations that predate current code-based billing infrastructure.

The practical effect: Group C drug billing relies on the standard oncology drug administration codes your team already uses. The NCD applies at the policy level, not the code level. Coverage determination flows from physician eligibility and NCI compliance — not from a specific code mapping.

Contact your MAC for guidance on which drug administration and drug supply codes to use on Group C drug claims. Code selection will depend on the route of administration and whether the drug is billed as an inpatient hospital service or an oral anticancer drug.

The three benefit categories named in this NCD — Drugs and Biologicals, Inpatient Hospital Services, and Oral Anticancer Drugs — give you the billing framework. Your MAC's local coverage determination or billing guidelines for oncology drugs will provide code-level specifics.